Market's view on Genincode
Published on April 2024
- Stock watcher expresses that once news is out, the market reaction will be explosive due to the low percentage of shares in public investor hands.
- Positive sentiment is shared for purchasing more shares due to a perceived temporary dip in stock price.
- Stock watcher highlights a significant delayed buy transaction, suggesting a premium was paid, indicating positive market activity.
- Optimism is noted about the company’s potential market cap growth, with expectations of growth into the hundreds of millions.
- Positive regulatory news (RNS) is mentioned as boosting stock price predictions.
- Stock watcher has been purchasing shares since December in anticipation of favorable FDA news related to a product called CARDIO inCode.
- Discussion includes a recent £4 million placement that is expected to fund the company for at least six months, delaying any potential fundraising activities.
- The company is described as undervalued compared to its market potential, particularly optimistic about upcoming FDA approval that could significantly increase company valuation.
- A recent endorsement by NICE for the ROCA test is seen as a positive sign for future approvals and reimbursements in other jurisdictions.
- There is a general sentiment that the market currently expects fundraising at lower prices despite company progress, but this is anticipated to realign with more positive valuations as progress is recognized.